Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338296 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
A Phase 4 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 4
- Development phase
- 278
- Enrollment target
NCT03338296 is a Phase 4 study that was terminated before completion, run by Eisai. The registered enrollment target is 278 participants.
The verdict
NCT03338296, a Phase 4 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 278 participants
- Enrollment target
Study Summary
This study will be conducted to demonstrate weight loss efficacy by change in body mass index (BMI) and safety in adolescents age 12 to 17 years (inclusive) during 52 weeks of treatment with Belviq XR 20 milligrams (mg) administered once daily (QD) as compared to placebo.
Interventions
- DRUG Placebo
- DRUG lorcaserin hydrochloride XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03338296
The ClinicalTrials.gov registry entry for NCT03338296 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03338296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03338296 about?
NCT03338296 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years". This study will be conducted to demonstrate weight loss efficacy by change in body mass index (BMI) and safety in adolescents age 12 to 17 years (inclusive) during 52 weeks of treatment with Belviq XR 20 milligrams (mg) administered once daily (QD) as compared to placebo.
What is the current status of trial NCT03338296?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 278 participants. The study started on 2017-09-28. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT03338296?
The interventions under investigation include: Placebo (DRUG), lorcaserin hydrochloride XR (DRUG).
Who is sponsoring clinical trial NCT03338296?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.